Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer
- 11 November 2005
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 13 (5) , 503-509
- https://doi.org/10.1038/sj.cgt.7700916
Abstract
We have designed a transgene that encodes a scFv(G250) chimeric receptor, which is specific for carboxyanhydrase IX (G250-ligand, G250L), a molecule overexpressed by renal cell cancer (RCC). Retroviral transduction of this transgene into primary human T lymphocytes confers these cells with specific functional responses towards G250L-positive RCC cells. In preparation of a clinical phase (I/II) study in RCC patients, we set up a protocol for gene transduction and expansion of primary human T cells. For this purpose, we directly compared two packaging cell lines, that is, the GALV-pseudotyped MLV producing cell line PG13, and the MLV-A-producing cell line Phi-NX-Ampho (a.k.a. Phoenix-A). We generated and characterized stable scFv(G250)-positive clones of both PG13 and Phoenix cells and optimized the retrovirus production conditions. Transductions of primary human T cells yielded 30–60% scFv(G250)+ T cells using PG13-derived retrovirus versus up to 90% scFv(G250)+ T cells using Phoenix-derived retrovirus. The median number of transgene integrations per scFv(G250)+ T cell differed only 1.5-fold as determined by real-time PCR (mean number of integrations per T cell 2.6 and 3.7 for PG13 and Phoenix-based transductions, respectively). In addition, T cells transduced with Phoenix-derived retrovirus showed, on a per cell basis, 10–30% higher levels of scFv(G250)-mediated TNF production and cytolysis of G250L+ RCC cells than T cells transduced with PG13-derived retrovirus. The improved functional transduction efficiency together with a limited increase in the number of integrations per recipient cell, made us select Phoenix clone 58 for our clinical immunogene therapy study.Keywords
This publication has 9 references indexed in Scilit:
- Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its ConsequencesMolecular Therapy, 2004
- Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell populationBlood, 2003
- Safety of retroviral gene marking with a truncated NGF receptorNature Medicine, 2003
- Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCRαβ Genes Into Primary Human T LymphocytesThe Journal of Immunology, 2003
- Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancerCancer Gene Therapy, 2002
- Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine productionGene Therapy, 2000
- Differential Inhibition of Retrovirus Transduction by Proteoglycans and Free GlycosaminoglycansBiotechnology Progress, 1999
- Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC TetramersThe Journal of Immunology, 1999
- A retroviral vector system ‘STITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytesGene Therapy, 1998